Fetterman appealed to President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. personally.

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

In a New York Times column this week, the Pennsylvania Democrat shared his experience taking Mounjaro while advocating for ...

President Trump directed his administration to help states import drugs from Canada. But a proposal to alter a Medicare ...

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the ...

The Centers for Medicare & Medicaid Services will not cover drugs when exclusively used for weight loss, like Ozempic or ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

Medicare Advantage insurers had urged CMS to scrap the obesity drug coverage proposals and eliminate a health equity payment ...

11 NEWS GETS THE FACTS ON OZEMPIC, WEGOVY ... not expected to be finalized until Trump took office. Medicare does pay for drugs like Wegovy for patients who have heart disease and need to reduce ...